Group Psychotherapy for People With HIV

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
David Spiegel, Stanford University
ClinicalTrials.gov Identifier:
NCT00186550
First received: September 13, 2005
Last updated: December 3, 2013
Last verified: December 2013
  Purpose

This study will examine the effectiveness of supportive-expressive group therapy plus education compared with an educational intervention in improving the quality of life and promoting health-enhancing behavior of men and women living with HIV or AIDS.


Condition Intervention
HIV
Depression
Risk-taking
Pain
Behavioral: Supportive Expressive Group Psychotherapy
Behavioral: Education

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Evaluation of Group Psychotherapy for People With HIV

Resource links provided by NLM:


Further study details as provided by Stanford University:

Enrollment: 186
Study Completion Date: November 2000
Detailed Description:

The major goal of this project is to examine the effectiveness of supportive-expressive group therapy plus education in comparison to an educationally intervention in improving the quality of life and promoting health-enhancing behavior of men and women living with HIV/AIDS.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1) a positive HIV diagnosis (either symptomatic or asymptomatic), 2) at least eighteen years of age, 3) English language skill (to complete questionnaires and participate, if assigned, to the group psychotherapy condition) and, 4) geographical proximity to groups in order to attend if assigned.

Exclusion Criteria:

  • 1) severe psychiatric disorders (i.e. schizophrenia or other psychotic disorders)who would not be appropriate for participating in the group intervention, 2) active tuberculosis, 3) acute intoxication, 4) participation in an ongoing HIV/AIDS support group or 5) suicidal/homicidal ideation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00186550

Locations
United States, California
Stanford University
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: David Spiegel, M.D. Stanford University
  More Information

Publications:

Responsible Party: David Spiegel, Jack, Lulu & Sam Willson Professor, Stanford University
ClinicalTrials.gov Identifier: NCT00186550     History of Changes
Other Study ID Numbers: R01 MH054930-04, R01MH054930-04
Study First Received: September 13, 2005
Last Updated: December 3, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Depression
Behavioral Symptoms

ClinicalTrials.gov processed this record on October 19, 2014